Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2026-03-19 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力2025年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制评价报告' which translates to '2025 Annual Internal Control Evaluation Report' for TianShiLi Pharmaceutical Group Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2025, including financial and non-financial internal control defects, their identification, and remediation status. The content is detailed and specific to internal control evaluation, which aligns with audit-related reporting rather than a full annual report or earnings release. There is no indication that this is a brief announcement or a presentation. The document is a standalone internal control evaluation report, which fits the category of Audit Report / Information (AR). The document length is 4739 characters, which is sufficient for a substantive report rather than a mere announcement. Therefore, the classification is AR with high confidence. FY 2025
2026-03-19 Chinese
天士力2025年度独立董事述职报告（徐宁）
Board/Management Information Classification · 95% confidence The document is titled as the "2025年度独立董事述职报告" which translates to "2025 Annual Independent Director's Work Report". It is a detailed report by an independent director about their duties, attendance, and activities during the year 2025. The content includes descriptions of board meetings attended, committee participation, communication with auditors, oversight of financial reports, and other governance-related activities. It is not a financial report like an annual or interim report, nor is it an announcement or proxy solicitation. It is a management-related report focusing on the independent director's role and activities, which fits best under Board/Management Information (MANG). The document length is 4411 characters, which is substantive and contains detailed narrative rather than a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2026-03-19 Chinese
天士力关于公司高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management member, specifically the vice general manager of the company. It details the resignation date, reasons, and impact on the company. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to shareholder votes or capital changes. The content fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2026-03-06 Chinese
天士力关于签署终止协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by TianShiLi Pharmaceutical Group Co., Ltd. regarding the signing of a termination agreement with Arbor Pharmaceuticals, LLC. It details the termination of a licensing agreement, the background of the parties involved, the main terms of the termination, and the impact on the company. The document is a formal public announcement about a corporate agreement termination and does not contain financial statements, audit information, or detailed financial results. It is not a report, transcript, or presentation but a regulatory announcement about a corporate event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-02-06 Chinese
天士力2025年度业绩快报
Earnings Release Classification · 95% confidence The document is titled as a '2025年度业绩快报' which translates to '2025 Annual Performance Express Report' or 'Annual Earnings Quick Report'. It contains preliminary financial data for the year 2025, including revenue, profit, and other key financial metrics. The text explicitly states that the data is preliminary, unaudited, and subject to change in the final annual report. The document length is 1432 characters, which is relatively short and consistent with a brief earnings release rather than a full annual report. There is no indication that this is a full audited annual report (10-K) or a detailed management discussion. It is an initial announcement of yearly financial results with key highlights, fitting the definition of an Earnings Release (ER). FY 2025
2026-02-06 Chinese
天士力2025年第六次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 6th extraordinary shareholders meeting in 2025 of TianShiLi Pharmaceutical Group Co., Ltd. It contains detailed voting results on various proposals, meeting attendance, and legal witness statements. The content focuses on the outcomes of shareholder votes on corporate governance changes, related party transactions, and appointment of auditors. It is not a full annual or interim report, nor a financial statement. It is not a call transcript or earnings release. The document is a formal announcement of the voting results from a shareholders meeting, including detailed vote counts and percentages. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is about 4661 characters, which is sufficient to include detailed voting results rather than just a brief announcement. Therefore, the correct classification is DVA with high confidence.
2025-12-26 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.